Drug Information

Drug (ID: DG00325) and It's Reported Resistant Information
Name
Bictegravir
Synonyms
Bictegravir; 1611493-60-7; GS-9883; UNII-8GB79LOJ07; GS-9883-01; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 8GB79LOJ07; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide; Bictegravir [INN]; Bictegravir [USAN:INN]; bictegravirum; GS 9883; Bictegravir (USAN/INN); CHEMBL3989866; SCHEMBL15914278; GTPL11575; CHEBI:172943; BDBM330048; AMY12383; BCP25703; EX-A3161; GS9883; s5911; DB11799; DT-0020; 2,5-Methanopyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazepine-10-carboxamide, 2,3,4,5,7,9,13,13a-octahydro-8-hydroxy-7,9-dioxo-N-((2,4,6-trifluorophenyl)methyl)-, (2R,5S,13aR)-; AC-30658; HY-17605; CS-0014685; D10909; N16998; US9663528, 42; A902376; Q27270406; GS-9883; GS 9883; GS9883; GS-9883-01; (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.0(2),(1)(1).0 , ]hexadeca-4,7-diene-7-carboxamide; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazepine-10-carboxamide
    Click to Show/Hide
Indication
In total 1 Indication(s)
Human immunodeficiency virus disease [ICD-11: 1C60-1C62]
Approved
[1]
Structure
Drug Resistance Disease(s)
Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
HIV infection [ICD-11: 1C62]
[2]
Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
HIV infection [ICD-11: 1C62]
[3]
Target Human immunodeficiency virus Integrase (HIV IN) POL_HV1B1 [1]
Human immunodeficiency virus Reverse transcriptase (HIV RT) POL_HV1B1 [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C21H18F3N3O5
IsoSMILES
C1C[C@@H]2C[C@H]1N3[C@H](O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
InChI
1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1
InChIKey
SOLUWJRYJLAZCX-LYOVBCGYSA-N
PubChem CID
90311989
DrugBank ID
DB11799
Type(s) of Resistant Mechanism of This Drug
  ADTT: Aberration of the Drug's Therapeutic Target
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
Click to Show/Hide the Resistance Disease of This Class
HIV infection [ICD-11: 1C62]
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
  Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148K+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.585
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.85
TM score: 0.94865
Amino acid change:
E10D+I72V+S123G+T124A+K127R+G140S+Q148K+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
10
|
E
D
E
E
H
H
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
20
|
R
R
A
A
M
M
A
A
S
S
D
D
F
F
N
N
L
L
P
P
30
|
P
P
V
V
V
V
A
A
K
K
E
E
I
I
V
V
A
A
S
S
40
|
C
C
D
D
K
K
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
50
|
M
M
H
H
G
G
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
60
|
I
I
W
W
Q
Q
L
L
D
D
C
C
T
T
H
H
L
L
E
E
70
|
G
G
K
K
I
V
I
I
L
L
V
V
A
A
V
V
H
H
V
V
80
|
A
A
S
S
G
G
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
90
|
P
P
A
A
E
E
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
100
|
F
F
L
L
L
L
K
K
L
L
A
A
G
G
R
R
W
W
P
P
110
|
V
V
K
K
T
T
I
I
H
H
T
T
D
D
N
N
G
G
S
S
120
|
N
N
F
F
T
T
S
G
T
A
T
T
V
V
K
R
A
A
A
A
130
|
C
C
W
W
W
W
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
140
|
G
S
I
I
P
P
Y
Y
N
N
P
P
Q
Q
S
S
Q
K
G
G
150
|
V
V
V
V
E
E
S
S
M
M
N
N
K
K
E
E
L
L
K
K
160
|
K
K
I
I
I
I
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
170
|
E
E
H
H
L
L
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
180
|
V
V
F
F
I
I
H
H
N
N
F
F
K
K
R
R
K
K
G
G
190
|
G
G
I
I
G
G
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
200
|
I
I
V
V
D
D
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
210
|
T
T
K
K
E
E
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
220
|
I
I
Q
Q
N
N
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
230
|
S
S
R
R
D
N
P
P
L
L
W
W
K
K
G
G
P
P
A
A
240
|
K
K
L
L
L
L
W
W
K
K
G
G
E
E
G
G
A
A
V
V
250
|
V
V
I
I
Q
Q
D
D
N
N
S
S
D
D
I
I
K
K
V
V
260
|
V
V
P
P
R
R
R
R
K
K
A
A
K
K
I
I
I
I
R
R
270
|
D
D
Y
Y
G
G
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
280
|
C
C
V
V
A
A
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E226Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.D6T+p.K7E+p.S17N+p.V54I+p.I72V+p.L74M+p.V79I+p.T97A+p.L101I+p.I113L+p.S119R+p.T122I+p.T124N+p.T125A+p.E138K+p.G140A+p.I141AT+p.S147SG+p.Q148R+p.K156N+p.I203M+p.I208M+p.L234V+p.D253E
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.975
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.96
TM score: 0.94366
Amino acid change:
D6T+K7E+S17N+V54I+I72V+L74M+V79I+T97A+L101I+I113L+S119R+T122I+T124N+T125A+E138K+G140A+I141AT+S147G+Q148R+K156N+I203M+I208M+L234V+D253E
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
D
D
G
G
I
I
D
T
K
E
A
A
Q
Q
10
|
D
D
E
E
H
H
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
20
|
R
R
A
A
M
M
A
A
S
S
D
D
F
F
N
N
L
L
P
P
30
|
P
P
V
V
V
V
A
A
K
K
E
E
I
I
V
V
A
A
S
S
40
|
C
C
D
D
K
K
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
50
|
M
M
H
H
G
G
Q
Q
V
I
D
D
C
C
S
S
P
P
G
G
60
|
I
I
W
W
Q
Q
L
L
D
D
C
C
T
T
H
H
L
L
E
E
70
|
G
G
K
K
I
V
I
I
L
M
V
V
A
A
V
V
H
H
V
I
80
|
A
A
S
S
G
G
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
90
|
P
P
A
A
E
E
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
100
|
F
F
L
I
L
L
K
K
L
L
A
A
G
G
R
R
W
W
P
P
110
|
V
V
K
K
T
T
I
L
H
H
T
T
D
D
N
N
G
G
S
R
120
|
N
N
F
F
T
I
G
G
T
N
T
A
V
V
R
R
A
A
A
A
130
|
C
C
W
W
W
W
A
A
G
G
I
I
K
K
Q
Q
E
K
F
F
140
|
G
A
I
A
P
P
Y
Y
N
N
P
P
Q
Q
S
G
Q
R
G
G
150
|
V
V
V
V
E
E
S
S
M
M
N
N
K
N
E
E
L
L
K
K
160
|
K
K
I
I
I
I
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
170
|
E
E
H
H
L
L
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
180
|
V
V
F
F
I
I
H
H
N
N
F
F
K
K
R
R
K
K
G
G
190
|
G
G
I
I
G
G
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
200
|
I
I
V
V
D
D
I
M
I
I
A
A
T
T
D
D
I
M
Q
Q
210
|
T
T
K
K
E
E
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
220
|
I
I
Q
Q
N
N
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
230
|
S
S
R
R
N
N
P
P
L
V
W
W
K
K
G
G
P
P
A
A
240
|
K
K
L
L
L
L
W
W
K
K
G
G
E
E
G
G
A
A
V
V
250
|
V
V
I
I
Q
Q
D
E
N
N
S
S
D
D
I
I
K
K
V
V
260
|
V
V
P
P
R
R
R
R
K
K
A
A
K
K
I
I
I
I
R
R
270
|
D
D
Y
Y
G
G
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
280
|
C
C
V
V
A
A
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q165H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E11D+p.K14R+p.S17T+p.V31I+p.L45V+p.A91S+p.L101I+p.T124A+p.E138Q+p.G140C+p.Q148R+p.V151I+p.K219N+p.N222K+p.L234I+p.V259I
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.772
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.15
TM score: 0.93594
Amino acid change:
E11D+K14R+S17T+V31I+L45V+A91S+L101I+T124A+E138Q+G140C+Q148R+V151I+K219N+N222K+L234I+V259I
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
10
|
D
D
E
D
H
H
E
E
K
R
Y
Y
H
H
S
T
N
N
W
W
20
|
R
R
A
A
M
M
A
A
S
S
D
D
F
F
N
N
L
L
P
P
30
|
P
P
V
I
V
V
A
A
K
K
E
E
I
I
V
V
A
A
S
S
40
|
C
C
D
D
K
K
C
C
Q
Q
L
V
K
K
G
G
E
E
A
A
50
|
M
M
H
H
G
G
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
60
|
I
I
W
W
Q
Q
L
L
D
D
C
C
T
T
H
H
L
L
E
E
70
|
G
G
K
K
V
V
I
I
L
L
V
V
A
A
V
V
H
H
V
V
80
|
A
A
S
S
G
G
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
90
|
P
P
A
S
E
E
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
100
|
F
F
L
I
L
L
K
K
L
L
A
A
G
G
R
R
W
W
P
P
110
|
V
V
K
K
T
T
I
I
H
H
T
T
D
D
N
N
G
G
S
S
120
|
N
N
F
F
T
T
G
G
T
A
T
T
V
V
R
R
A
A
A
A
130
|
C
C
W
W
W
W
A
A
G
G
I
I
K
K
Q
Q
E
Q
F
F
140
|
G
C
I
I
P
P
Y
Y
N
N
P
P
Q
Q
S
S
Q
R
G
G
150
|
V
V
V
I
E
E
S
S
M
M
N
N
K
K
E
E
L
L
K
K
160
|
K
K
I
I
I
I
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
170
|
E
E
H
H
L
L
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
180
|
V
V
F
F
I
I
H
H
N
N
F
F
K
K
R
R
K
K
G
G
190
|
G
G
I
I
G
G
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
200
|
I
I
V
V
D
D
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
210
|
T
T
K
K
E
E
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
N
220
|
I
I
Q
Q
N
K
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
230
|
S
S
R
R
N
N
P
P
L
I
W
W
K
K
G
G
P
P
A
A
240
|
K
K
L
L
L
L
W
W
K
K
G
G
E
E
G
G
A
A
V
V
250
|
V
V
I
I
Q
Q
D
D
N
N
S
S
D
D
I
I
K
K
V
I
260
|
V
V
P
P
R
R
R
R
K
K
A
A
K
K
I
I
I
I
R
R
270
|
D
D
Y
Y
G
G
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
280
|
C
C
V
V
A
A
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q163H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E11D+p.V31I+p.G70R+p.I84V+p.L101I+p.S119P+p.T122I+p.N155H+p.G163E+p.V201I+p.D256E
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.457
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.14
TM score: 0.94195
Amino acid change:
E11D+V31I+G70R+I84V+L101I+S119P+T122I+N155H+G163E+V201I+D256E
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
10
|
D
D
E
D
H
H
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
20
|
R
R
A
A
M
M
A
A
S
S
D
D
F
F
N
N
L
L
P
P
30
|
P
P
V
I
V
V
A
A
K
K
E
E
I
I
V
V
A
A
S
S
40
|
C
C
D
D
K
K
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
50
|
M
M
H
H
G
G
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
60
|
I
I
W
W
Q
Q
L
L
D
D
C
C
T
T
H
H
L
L
E
E
70
|
G
R
K
K
V
V
I
I
L
L
V
V
A
A
V
V
H
H
V
V
80
|
A
A
S
S
G
G
Y
Y
I
V
E
E
A
A
E
E
V
V
I
I
90
|
P
P
A
A
E
E
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
100
|
F
F
L
I
L
L
K
K
L
L
A
A
G
G
R
R
W
W
P
P
110
|
V
V
K
K
T
T
I
I
H
H
T
T
D
D
N
N
G
G
S
P
120
|
N
N
F
F
T
I
G
G
A
A
T
T
V
V
R
R
A
A
A
A
130
|
C
C
W
W
W
W
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
140
|
G
G
I
I
P
P
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
150
|
V
V
V
V
E
E
S
S
M
M
N
H
K
K
E
E
L
L
K
K
160
|
K
K
I
I
I
I
G
E
Q
Q
V
V
R
R
D
D
Q
Q
A
A
170
|
E
E
H
H
L
L
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
180
|
V
V
F
F
I
I
H
H
N
N
F
F
K
K
R
R
K
K
G
G
190
|
G
G
I
I
G
G
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
200
|
I
I
V
I
D
D
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
210
|
T
T
K
K
E
E
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
220
|
I
I
Q
Q
N
N
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
230
|
S
S
R
R
N
N
P
P
L
L
W
W
K
K
G
G
P
P
A
A
240
|
K
K
L
L
L
L
W
W
K
K
G
G
E
E
G
G
A
A
V
V
250
|
V
V
I
I
Q
Q
D
D
N
N
S
S
D
E
I
I
K
K
V
V
260
|
V
V
P
P
R
R
R
R
K
K
A
A
K
K
I
I
I
I
R
R
270
|
D
D
Y
Y
G
G
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
280
|
C
C
V
V
A
A
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q161H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.S24G+p.D25E+p.S39C+p.I60IM+p.L63I+p.T97A+p.L101I+p.S119SR+p.T124N+p.T125A+p.I135V+p.E138T+p.G140S+p.Q148H+p.M154I+p.V165I+p.V201I+p.V259VI
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.011
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.86
TM score: 0.95222
Amino acid change:
K14R+S24G+D25E+S39C+I60M+L63I+T97A+L101I+S119R+T124N+T125A+I135V+E138T+G140S+Q148H+M154I+V165I+V201I+V259I
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
G
D
E
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
C
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
M
W
W
Q
Q
1210
|
L
I
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
R
N
N
F
F
T
T
1270
|
G
G
T
N
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
V
K
K
Q
Q
E
T
F
F
G
S
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
H
G
G
V
V
V
V
E
E
1300
|
S
S
M
I
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
I
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
I
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q164H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E11D+p.S17C+p.L68V+p.L101I+p.T124N+p.T125A+p.I135V+p.G140A+p.Q148R+p.D253E+p.V281M
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.975
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 2
TM score: 0.90394
Amino acid change:
E11D+S17C+L68V+L101I+T124N+T125A+I135V+G140A+Q148R+D253E+V281M
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
D
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
C
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
V
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
N
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
V
K
K
Q
Q
E
E
F
F
G
A
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
R
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
E
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
M
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q162H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.E69ED+p.E138K+p.G140S+p.Q148H+p.M154I+p.N155H+p.V201I
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.004
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.04
TM score: 0.94414
Amino acid change:
K14R+E69D+E138K+G140S+Q148H+M154I+N155H+V201I
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
D
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
K
F
F
G
S
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
H
G
G
V
V
V
V
E
E
1300
|
S
S
M
I
N
H
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q166H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S17N+p.M50L+p.I72V+p.Q95QH+p.T112V+p.I113V+p.T124A+p.T125A+p.G134D+p.V201I+p.Q221QKR+p.L234I+p.D256E
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.345
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.92
TM score: 0.9476
Amino acid change:
S17N+M50L+I72V+Q95H+T112V+I113V+T124A+T125A+G134D+V201I+Q221KR+L234I+D256E
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
L
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
H
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
V
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
D
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
K
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
E
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.V31I+p.I72V+p.T112V+p.I113V+p.T124A+p.T125A+p.G134N+p.I135V+p.D167E+p.V201I+p.T206S+p.I208L+p.N222K+p.L234I+p.A265V+p.R269K+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.188
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1
TM score: 0.94233
Amino acid change:
K14R+V31I+I72V+T112V+I113V+T124A+T125A+G134N+I135V+D167E+V201I+T206S+I208L+N222K+L234I+A265V+R269K+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
I
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
V
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
N
I
V
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
E
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
S
D
D
I
L
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
K
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
V
K
K
I
I
I
I
R
K
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L101I+p.T122I+p.T124N+p.A265V
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.882
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.92
TM score: 0.94699
Amino acid change:
L101I+T122I+T124N+A265V
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
I
1270
|
G
G
T
N
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
V
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S17N+p.L28I+p.P30A+p.I84L+p.S119T+p.T124A+p.K136Q+p.V165I+p.I200T+p.V201I+p.K211R+p.T218I+p.L234V+p.D256E+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.161
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.44
TM score: 0.92807
Amino acid change:
S17N+L28I+P30A+I84L+S119T+T124A+K136Q+V165I+I200T+V201I+K211R+T218I+L234V+D256E+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
I
P
P
P
A
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
L
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
T
N
N
F
F
T
T
1270
|
G
G
T
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
Q
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
I
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
T
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
R
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
I
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
V
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
E
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E11D+p.D25E+p.V31I+p.F100Y+p.L101I+p.T112V+p.S119P+p.K136Q+p.V201I+p.T218I+p.L234I+p.A265V+p.R269K+p.D278A+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.612
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 2.17
TM score: 0.90707
Amino acid change:
E11D+D25E+V31I+F100Y+L101I+T112V+S119P+K136Q+V201I+T218I+L234I+A265V+R269K+D278A+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
D
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
E
F
F
N
N
L
L
P
P
P
P
V
I
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
Y
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
Q
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
I
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
V
K
K
I
I
I
I
R
K
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
A
D
D
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.G59D+p.I60V+p.E138K+p.Q148R+p.K173R+p.T218S+p.S230N+p.M275S+p.C280S
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q160H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T97A+p.G163R
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G163R.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T122I
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T122I.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.NULL
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included NULL.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.I72A+p.N155H
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E157K
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E157K.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E92Q
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S147G
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S147G.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.G140E
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140E.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.N155H
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N155H.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L234F
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L234F.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S24G+p.N155H+p.D253E
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24G, N155H, D253E.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E92Q+p.G140A
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, G140A.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S153F
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153F.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T66I+p.R263K
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L45Q+p.T115H
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L45Q, T115H.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.R263K
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R263K.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E138K+p.Q148R
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S153Y
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S153Y
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.Q148R+p.N155H
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T66I+p.Q148K
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S153Y+p.L234F
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y, L234F.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.G140A+p.Q148R
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T97A+p.G118R
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.G118R
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G118R.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T66I+p.E138K+p.Q148R
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E138K+p.Q148K
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E138K+p.G140A+p.Q148R
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T66I+p.E138K+p.Q148K
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148K.
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
  Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148H+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.626
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.91
TM score: 0.9455
Amino acid change:
E10D+I72V+S123G+T124A+K127R+G140S+Q148H+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
S
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
H
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E224Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.84
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.93
TM score: 0.94573
Amino acid change:
E10D+I72V+S123G+T124A+K127R+G140S+Q148R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
S
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
R
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E223Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.E157Q+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.646
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.84
TM score: 0.94985
Amino acid change:
E10D+I72V+S123G+T124A+K127R+N155H+E157Q+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
H
K
K
E
Q
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E221Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.882
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 2.1
TM score: 0.88224
Amino acid change:
E10D+I72V+S119P+S123G+T124A+K127R+N155H+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
H
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E207Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.803
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1
TM score: 0.94631
Amino acid change:
E10D+M50I+I72V+S123G+T124A+K127R+N155H+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
I
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
H
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E218Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.E157Q+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.431
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.8
TM score: 0.95061
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Q148R+E157Q+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
R
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
Q
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E193Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.614
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.81
TM score: 0.95013
Amino acid change:
E10D+I72V+S119P+S123G+T124A+K127R+Q148R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
R
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E200Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.988
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.83
TM score: 0.9497
Amino acid change:
E10D+M50I+I72V+S123G+T124A+K127R+Q148R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
I
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
R
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E178Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.E157Q+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.081
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.77
TM score: 0.95113
Amino acid change:
E10D+I72V+S123G+T124A+K127R+S147G+E157Q+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
G
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
Q
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E213Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.949
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.81
TM score: 0.95024
Amino acid change:
E10D+I72V+S119P+S123G+T124A+K127R+S147G+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
G
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E199Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.838
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.81
TM score: 0.94952
Amino acid change:
E10D+M50I+I72V+S123G+T124A+K127R+S147G+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
I
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
G
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E192Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.844
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.89
TM score: 0.94783
Amino acid change:
E10D+I72V+E92Q+S123G+T124A+K127R+E157Q+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
Q
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
Q
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E212Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.E92Q+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.952
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.97
TM score: 0.94406
Amino acid change:
E10D+I72V+E92Q+S119P+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
Q
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E217Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.M50I+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.419
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.11
TM score: 0.94131
Amino acid change:
E10D+M50I+I72V+E92Q+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
I
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
Q
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E204Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.098
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.86
TM score: 0.94926
Amino acid change:
E10D+T66I+I72V+S123G+T124A+K127R+E157Q+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
I
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
Q
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E162Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.T66I+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.357
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.89
TM score: 0.94778
Amino acid change:
E10D+T66I+I72V+S119P+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
I
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E161Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.M50I+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.344
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.9
TM score: 0.94725
Amino acid change:
E10D+M50I+T66I+I72V+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
I
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
I
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E160Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E170A+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.934
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.92
TM score: 0.9467
Amino acid change:
E10D+I72V+S123G+T124A+K127R+E170A+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
A
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E191Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G163K+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.915
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.88
TM score: 0.94863
Amino acid change:
E10D+I72V+S123G+T124A+K127R+G163K+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
K
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E190Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.823
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.86
TM score: 0.94911
Amino acid change:
E10D+I72V+S123G+T124A+K127R+E157Q+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
Q
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E206Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157K+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.67
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.01
TM score: 0.94529
Amino acid change:
E10D+I72V+S123G+T124A+K127R+E157K+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
K
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E216Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153Y+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.444
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.46
TM score: 0.93775
Amino acid change:
E10D+I72V+S123G+T124A+K127R+S153Y+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
Y
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E220Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153F+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.101
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.24
TM score: 0.93905
Amino acid change:
E10D+I72V+S123G+T124A+K127R+S153F+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
F
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E219Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153A+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.227
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.09
TM score: 0.94314
Amino acid change:
E10D+I72V+S123G+T124A+K127R+S153A+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
A
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E198Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151L+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.653
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.79
TM score: 0.95078
Amino acid change:
E10D+I72V+S123G+T124A+K127R+V151L+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
L
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E189Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151A+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.213
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.95
TM score: 0.94439
Amino acid change:
E10D+I72V+S123G+T124A+K127R+V151A+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
A
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E177Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.525
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.98
TM score: 0.94446
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Q146R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
R
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E211Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146P+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.737
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.08
TM score: 0.94389
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Q146P+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
P
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E159Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146L+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.411
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.01
TM score: 0.94906
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Q146L+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
L
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E215Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146K+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 69.778
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.76
TM score: 0.54519
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Q146K+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
K
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E188Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146I+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 70.355
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.32
TM score: 0.69499
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Q146I+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
I
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E225Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.P145S+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.247
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.85
TM score: 0.94982
Amino acid change:
E10D+I72V+S123G+T124A+K127R+P145S+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
S
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E157Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.257
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.91
TM score: 0.9456
Amino acid change:
E10D+I72V+S123G+T124A+K127R+G140S+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
S
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E181Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140C+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.778
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.99
TM score: 0.94751
Amino acid change:
E10D+I72V+S123G+T124A+K127R+G140C+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
C
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E165Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140A+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.649
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.86
TM score: 0.94873
Amino acid change:
E10D+I72V+S123G+T124A+K127R+G140A+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
A
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E170Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138K+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.111
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.96
TM score: 0.94514
Amino acid change:
E10D+I72V+S123G+T124A+K127R+E138K+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
K
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E180Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138A+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.263
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.93
TM score: 0.94631
Amino acid change:
E10D+I72V+S123G+T124A+K127R+E138A+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
A
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E176Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.A128T+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.825
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.98
TM score: 0.94358
Amino acid change:
E10D+I72V+S123G+T124A+K127R+A128T+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
T
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E197Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.Q95R+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.746
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.88
TM score: 0.94919
Amino acid change:
E10D+I72V+Q95R+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
R
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E196Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.Q95K+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.97
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.91
TM score: 0.94748
Amino acid change:
E10D+I72V+Q95K+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
K
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E187Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72T+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.046
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.92
TM score: 0.94688
Amino acid change:
E10D+I72T+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
T
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E175Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72N+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.974
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.94
TM score: 0.94608
Amino acid change:
E10D+I72N+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
N
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E167Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72A+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.021
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.91
TM score: 0.9471
Amino acid change:
E10D+I72A+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
A
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E166Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.L68V+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.024
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.89
TM score: 0.94862
Amino acid change:
E10D+L68V+I72V+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
V
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E174Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.L68I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.114
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.94
TM score: 0.94659
Amino acid change:
E10D+L68I+I72V+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
I
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E169Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.H51Y+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.596
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.82
TM score: 0.95098
Amino acid change:
E10D+H51Y+I72V+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
Y
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E203Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N+p.R263K
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.649
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.8
TM score: 0.95002
Amino acid change:
E10D+I72V+S123G+T124A+K127R+D232N+R263K
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
K
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E222Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.203
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.83
TM score: 0.94879
Amino acid change:
E10D+I72V+S123G+T124A+K127R+N155H+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
H
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E210Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.686
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.83
TM score: 0.94983
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Q148R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
R
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E173Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148K+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.483
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.84
TM score: 0.95023
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Q148K+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
K
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E186Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148H+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.704
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.84
TM score: 0.94821
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Q148H+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
H
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E172Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.607
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.84
TM score: 0.94943
Amino acid change:
E10D+I72V+S123G+T124A+K127R+S147G+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
G
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E195Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.567
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.93
TM score: 0.94639
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Y143R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
R
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E209Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143H+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.08
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.94
TM score: 0.94449
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Y143H+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
H
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E185Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143C+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.529
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.03
TM score: 0.94608
Amino acid change:
E10D+I72V+S123G+T124A+K127R+Y143C+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
C
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E184Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.029
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.94
TM score: 0.94621
Amino acid change:
E10D+I72V+E92Q+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
Q
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E205Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.I72V+p.E92G+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 72.411
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.28
TM score: 0.93813
Amino acid change:
E10D+I72V+E92G+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
G
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E208Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.T66K+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.649
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.97
TM score: 0.94411
Amino acid change:
E10D+T66K+I72V+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
K
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E214Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.33
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.9
TM score: 0.94806
Amino acid change:
E10D+T66I+I72V+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
I
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E158Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.T66A+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.085
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1
TM score: 0.9441
Amino acid change:
E10D+T66A+I72V+S123G+T124A+K127R+D232N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
A
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
S
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E164Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E10D+p.S17T+p.S39N+p.I72V+p.S119P+p.T122I+p.T124N+p.T125A+p.V151I+p.N155H+p.N222K+p.P261A
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.551
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.9
TM score: 0.94823
Amino acid change:
E10D+S17T+S39N+I72V+S119P+T122I+T124N+T125A+V151I+N155H+N222K+P261A
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
E
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
T
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
N
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
I
1270
|
G
G
T
N
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
I
E
E
1300
|
S
S
M
M
N
H
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
K
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
A
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q155H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S17N+p.S39R+p.L45V+p.M50ML+p.T66A+p.V75I+p.L101I+p.T124A+p.K127R+p.S147SG+p.G163K+p.V201I
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.462
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.95
TM score: 0.94713
Amino acid change:
S17N+S39R+L45V+M50L+T66A+V75I+L101I+T124A+K127R+S147G+G163K+V201I
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
R
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
V
K
K
G
G
E
E
A
A
M
L
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
A
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
I
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
T
V
V
K
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
G
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
K
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q148H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.A23T+p.S24G+p.D25E+p.L28I+p.I72V+p.T124A+p.Q148R+p.V165I+p.L172LF+p.H183HP+p.Q209QP+p.A239AT
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.352
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.26
TM score: 0.94164
Amino acid change:
A23T+S24G+D25E+L28I+I72V+T124A+Q148R+V165I+L172F+H183P+Q209P+A239T
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
T
S
G
D
E
F
F
N
N
L
I
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
R
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
I
R
R
D
D
Q
Q
A
A
E
E
H
H
L
F
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
P
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
P
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
T
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q150H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K7KR+p.S17N+p.I72V+p.I84L+p.T97A+p.L101I+p.T112I+p.S119P+p.T122I+p.T124N+p.T125A+p.K136Q+p.Y143R+p.V201I+p.A205S+p.K211R+p.T218L+p.L234V+p.D256E+p.I268L+p.D270H
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.893
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.33
TM score: 0.93617
Amino acid change:
K7R+S17N+I72V+I84L+T97A+L101I+T112I+S119P+T122I+T124N+T125A+K136Q+Y143R+V201I+A205S+K211R+T218L+L234V+D256E+I268L+D270H
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
R
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
L
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
I
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
I
1270
|
G
G
T
N
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
Q
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
R
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
S
T
T
D
D
I
I
Q
Q
T
T
K
R
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
L
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
V
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
E
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
L
R
R
D
H
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q157H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S17N+p.M154L+p.N155H+p.V201I+p.D232N+p.L242LF
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.66
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.98
TM score: 0.94753
Amino acid change:
S17N+M154L+N155H+V201I+D232N+L242F
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
L
N
H
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
D
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
F
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q154H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.V31I+p.V32I+p.L45Q+p.L101I+p.T112V+p.T125A+p.G134N+p.I135V+p.K136T+p.Y143C+p.V201I+p.T206S+p.S230R+p.L234I+p.N254NS+p.R269K+p.D270H
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.008
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.12
TM score: 0.93557
Amino acid change:
K14R+V31I+V32I+L45Q+L101I+T112V+T125A+G134N+I135V+K136T+Y143C+V201I+T206S+S230R+L234I+N254S+R269K+D270H
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
I
V
I
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
Q
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
A
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
N
I
V
K
T
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
C
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
S
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
R
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
S
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
K
D
H
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q158H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.S24H+p.V31I+p.L68I+p.I73V+p.E92Q+p.L101I+p.T112V+p.S119T+p.T124G+p.T125A+p.G134N+p.K136T+p.V165I+p.V201I+p.T206S+p.L234I+p.D256E+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.995
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.63
TM score: 0.91157
Amino acid change:
K14R+S24H+V31I+L68I+I73V+E92Q+L101I+T112V+S119T+T124G+T125A+G134N+K136T+V165I+V201I+T206S+L234I+D256E+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
H
D
D
F
F
N
N
L
L
P
P
P
P
V
I
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
I
E
E
G
G
K
K
V
V
1220
|
I
V
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
Q
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
T
N
N
F
F
T
T
1270
|
G
G
T
G
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
N
I
I
K
T
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
I
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
S
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
E
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q149H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.V31I+p.T97A+p.L101I+p.T112V+p.S119R+p.T124A+p.T125S+p.G134N+p.K136T+p.N155H+p.V165I+p.V201I+p.T206S+p.Y227F+p.L234I+p.S255N+p.D256E+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.006
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.06
TM score: 0.94159
Amino acid change:
K14R+V31I+T97A+L101I+T112V+S119R+T124A+T125S+G134N+K136T+N155H+V165I+V201I+T206S+Y227F+L234I+S255N+D256E+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
I
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
R
N
N
F
F
T
T
1270
|
G
G
T
A
T
S
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
N
I
I
K
T
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
H
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
I
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
S
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
F
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
N
D
E
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q153H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S17N+p.R20K+p.M50I+p.V77A+p.L101I+p.T112I+p.T124A+p.T125A+p.K136Q+p.G193E+p.V201I+p.T206S+p.T218L+p.I220V+p.L234V+p.D256E+p.R263K+p.D279G+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.488
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.49
TM score: 0.94371
Amino acid change:
S17N+R20K+M50I+V77A+L101I+T112I+T124A+T125A+K136Q+G193E+V201I+T206S+T218L+I220V+L234V+D256E+R263K+D279G+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
R
K
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
I
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
A
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
I
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
Q
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
E
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
S
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
L
K
K
I
V
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
V
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
E
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
K
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
G
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q151H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.E11D+p.R20K+p.E92Q+p.V201I+p.K211R+p.S230SN+p.D232E+p.D256E
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.87
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.22
TM score: 0.93275
Amino acid change:
E11D+R20K+E92Q+V201I+K211R+S230N+D232E+D256E
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
D
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
K
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
Q
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
R
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
N
R
R
D
E
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
E
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q152H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.L101V+p.T112I+p.T125V+p.N155H+p.E157Q+p.K160Q+p.G193E+p.S230N+p.L234I+p.A265V+p.D279G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 72.839
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 2.38
TM score: 0.86291
Amino acid change:
K14R+L101V+T112I+T125V+N155H+E157Q+K160Q+G193E+S230N+L234I+A265V+D279G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
V
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
I
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
A
A
T
V
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
H
K
K
E
Q
L
L
K
K
K
Q
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
E
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
N
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
V
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
G
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q156H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [4]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S17N+p.D25E+p.S119G+p.T122I+p.T124N+p.T125A+p.M154I+p.N155H+p.K156R+p.T206S+p.T218S
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.293
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.85
TM score: 0.95032
Amino acid change:
S17N+D25E+S119G+T122I+T124N+T125A+M154I+N155H+K156R+T206S+T218S
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
E
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
G
N
N
F
F
T
I
1270
|
G
G
T
N
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
I
N
H
K
R
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
S
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
S
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q159H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.I5V+p.S17N+p.M50L+p.E69G+p.I72V+p.T112I+p.I113V+p.T124A+p.T125A+p.T174A+p.V201I+p.T218I+p.L234I+p.D256E
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.695
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.09
TM score: 0.93943
Amino acid change:
I5V+S17N+M50L+E69G+I72V+T112I+I113V+T124A+T125A+T174A+V201I+T218I+L234I+D256E
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
V
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
L
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
G
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
I
1260
|
I
V
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
A
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
I
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
E
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K42Q+p.L101I+p.T112V+p.T124A+p.T125A+p.K136Q+p.G163R+p.V201I+p.L234I+p.R269K+p.D278A+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.483
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.23
TM score: 0.93778
Amino acid change:
K42Q+L101I+T112V+T124A+T125A+K136Q+G163R+V201I+L234I+R269K+D278A+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
Q
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
Q
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
R
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
K
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
A
D
D
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.V31I+p.L74I+p.L101I+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136T+p.H171Q+p.V201I+p.T206S+p.I208M+p.T218I+p.L234I+p.A265V+p.R269K+p.D286N
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 71.341
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.66
TM score: 0.90282
Amino acid change:
K14R+V31I+L74I+L101I+T112V+T124A+T125A+G134N+I135V+K136T+H171Q+V201I+T206S+I208M+T218I+L234I+A265V+R269K+D286N
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
I
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
I
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
N
I
V
K
T
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
Q
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
S
D
D
I
M
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
I
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
V
K
K
I
I
I
I
R
K
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
N
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S17N+p.I72V+p.I84V+p.T124A+p.M154I+p.K173R
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.501
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.82
TM score: 0.95069
Amino acid change:
S17N+I72V+I84V+T124A+M154I+K173R
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
N
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
V
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
I
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
R
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L101I+p.T125A+p.I135V+p.D167DE+p.G193R+p.V201I+p.I208L+p.K211T+p.A265V+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.45
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 0.88
TM score: 0.9496
Amino acid change:
L101I+T125A+I135V+D167E+G193R+V201I+I208L+K211T+A265V+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
I
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
A
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
V
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
E
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
R
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
L
Q
Q
T
T
K
T
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
V
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.A21T+p.A23V+p.S39N+p.I72V+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136R+p.D167E+p.V201I+p.L234I+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.133
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.15
TM score: 0.94107
Amino acid change:
K14R+A21T+A23V+S39N+I72V+T112V+T124A+T125A+G134N+I135V+K136R+D167E+V201I+L234I+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
T
M
M
1170
|
A
V
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
N
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
N
I
V
K
R
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
E
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.K14R+p.A21T+p.V31I+p.V32I+p.M50I+p.I72V+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136R+p.D167E+p.V201I+p.T206S+p.L234I+p.S283G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.783
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.24
TM score: 0.93477
Amino acid change:
K14R+A21T+V31I+V32I+M50I+I72V+T112V+T124A+T125A+G134N+I135V+K136R+D167E+V201I+T206S+L234I+S283G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
R
Y
Y
H
H
S
S
N
N
W
W
R
R
A
T
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
I
V
I
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
I
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
I
V
1220
|
I
I
L
L
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
V
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
T
A
T
A
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
N
I
V
K
R
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
E
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
I
D
D
1350
|
I
I
I
I
A
A
T
S
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
I
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
G
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.T97A+p.S119G
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.492
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.55
TM score: 0.93871
Amino acid change:
L74M+T97A+S119G
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
G
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.T97A
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.068
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.86
TM score: 0.90784
Amino acid change:
L74M+T97A
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.T97A
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.068
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.86
TM score: 0.90784
Amino acid change:
L74M+T97A
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
S
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.T97A+p.S119T
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 75.127
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 2.1
TM score: 0.89697
Amino acid change:
L74M+T97A+S119T
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
T
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.T97A+p.S119P
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 73.599
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.17
TM score: 0.93805
Amino acid change:
L74M+T97A+S119P
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.T97A+p.S119R
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.412
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.62
TM score: 0.93508
Amino acid change:
L74M+T97A+S119R
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
R
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.T97A+p.S119R
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.412
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.62
TM score: 0.93508
Amino acid change:
L74M+T97A+S119R
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
A
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
R
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.S119P
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.456
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.22
TM score: 0.9419
Amino acid change:
L74M+S119P
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
P
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.S119R
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.816
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.04
TM score: 0.93189
Amino acid change:
L74M+S119R
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
R
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M+p.S119R
 Molecule Info 
Wild Type Structure Method: AlphaFold  Average pLDDT: 75.736
Click to Show/Hide The PAE Picture
Mutant Type Structure Method: AlphaFold  Average pLDDT: 74.816
Click to Show/Hide The PAE Picture
   Download The Information of Sequence       Download The Structure File   
RMSD: 1.04
TM score: 0.93189
Amino acid change:
L74M+S119R
 : Wild Type Structure
 : Mutant Type Structure
  Mutation site(s) have been marked in red
-
F
F
L
L
1150
|
D
D
G
G
I
I
D
D
K
K
A
A
Q
Q
D
D
E
E
H
H
1160
|
E
E
K
K
Y
Y
H
H
S
S
N
N
W
W
R
R
A
A
M
M
1170
|
A
A
S
S
D
D
F
F
N
N
L
L
P
P
P
P
V
V
V
V
1180
|
A
A
K
K
E
E
I
I
V
V
A
A
S
S
C
C
D
D
K
K
1190
|
C
C
Q
Q
L
L
K
K
G
G
E
E
A
A
M
M
H
H
G
G
1200
|
Q
Q
V
V
D
D
C
C
S
S
P
P
G
G
I
I
W
W
Q
Q
1210
|
L
L
D
D
C
C
T
T
H
H
L
L
E
E
G
G
K
K
V
V
1220
|
I
I
L
M
V
V
A
A
V
V
H
H
V
V
A
A
S
S
G
G
1230
|
Y
Y
I
I
E
E
A
A
E
E
V
V
I
I
P
P
A
A
E
E
1240
|
T
T
G
G
Q
Q
E
E
T
T
A
A
Y
Y
F
F
L
L
L
L
1250
|
K
K
L
L
A
A
G
G
R
R
W
W
P
P
V
V
K
K
T
T
1260
|
I
I
H
H
T
T
D
D
N
N
G
G
S
R
N
N
F
F
T
T
1270
|
G
G
A
A
T
T
V
V
R
R
A
A
A
A
C
C
W
W
W
W
1280
|
A
A
G
G
I
I
K
K
Q
Q
E
E
F
F
G
G
I
I
P
P
1290
|
Y
Y
N
N
P
P
Q
Q
S
S
Q
Q
G
G
V
V
V
V
E
E
1300
|
S
S
M
M
N
N
K
K
E
E
L
L
K
K
K
K
I
I
I
I
1310
|
G
G
Q
Q
V
V
R
R
D
D
Q
Q
A
A
E
E
H
H
L
L
1320
|
K
K
T
T
A
A
V
V
Q
Q
M
M
A
A
V
V
F
F
I
I
1330
|
H
H
N
N
F
F
K
K
R
R
K
K
G
G
G
G
I
I
G
G
1340
|
G
G
Y
Y
S
S
A
A
G
G
E
E
R
R
I
I
V
V
D
D
1350
|
I
I
I
I
A
A
T
T
D
D
I
I
Q
Q
T
T
K
K
E
E
1360
|
L
L
Q
Q
K
K
Q
Q
I
I
T
T
K
K
I
I
Q
Q
N
N
1370
|
F
F
R
R
V
V
Y
Y
Y
Y
R
R
D
D
S
S
R
R
N
N
1380
|
P
P
L
L
W
W
K
K
G
G
P
P
A
A
K
K
L
L
L
L
1390
|
W
W
K
K
G
G
E
E
G
G
A
A
V
V
V
V
I
I
Q
Q
1400
|
D
D
N
N
S
S
D
D
I
I
K
K
V
V
V
V
P
P
R
R
1410
|
R
R
K
K
A
A
K
K
I
I
I
I
R
R
D
D
Y
Y
G
G
1420
|
K
K
Q
Q
M
M
A
A
G
G
D
D
D
D
C
C
V
V
A
A
1430
|
S
S
R
R
Q
Q
D
D
E
E
D
D
Click to Show/Hide the Structure
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.G163R
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E202Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.F121Y
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E163Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S119T
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E183Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S119R
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E201Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S119P
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E182Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.S119G
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E179Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E171Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.M50I
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E194Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [1]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T97A
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E168Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT) [2]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.V88I+p.M154I
 Molecule Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T97A+p.S119G
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T97A+p.S119T
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T97V
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97V.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M.
Key Molecule: HIV1 Integrase (HIV1 IT) [5]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T66I
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T97A+p.G118R+p.S119R
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.L74M
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T97A+p.S119P
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT) [3]
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
 Disease Info 
Molecule Alteration Missense mutation
p.T97A
 Molecule Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A.
References
Ref 1 Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na ve individuals. J Med Virol. 2019 Dec;91(12):2188-2194. doi: 10.1002/jmv.25564. Epub 2019 Aug 20.
Ref 2 Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. doi: 10.1128/AAC.01474-16. Print 2016 Dec.
Ref 3 Bictegravir Resistance Profile: Data for External Experts.
Ref 4 Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01717-19. doi: 10.1128/AAC.01717-19. Print 2019 Dec 20.
Ref 5 Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.